What is Bio-Synthesis?
Bio-Synthesis Inc operates as a critical infrastructure provider for the life sciences industry, specializing in the complex synthesis of peptides, oligonucleotides, DNA, and RNA. By offering bespoke bioconjugation and molecular biology applications, the firm serves as a vital partner for academic institutions and commercial R&D organizations. Their comprehensive portfolio, which includes modified oligonucleotides and high-precision analytical services, enables researchers to overcome technical barriers in drug discovery and genomic exploration. As a specialized service provider, Bio-Synthesis maintains a robust market position by ensuring high-quality, customized solutions that meet the rigorous demands of modern biotechnology research.
How much funding has Bio-Synthesis raised?
Bio-Synthesis has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in Bio-Synthesis
PPP
Public-Private Partnership
What's next for Bio-Synthesis?
With the infusion of $350K, Bio-Synthesis is poised to scale its production capacity and enhance its technological infrastructure. The strategic allocation of this capital will likely focus on optimizing synthesis workflows and expanding the company's catalog of specialized molecular tools. As the life sciences sector continues to prioritize rapid innovation in therapeutic development, Bio-Synthesis is strategically aligned to capture increased demand for high-fidelity biological materials. Future growth initiatives will likely involve deepening their integration into the pharmaceutical supply chain and potentially exploring new frontiers in synthetic biology, ensuring the company remains at the forefront of scientific advancement.
See full Bio-Synthesis company page
